Background Preterm labor (PTL) is a common and serious pregnancy disorder that can
cause long-term neurological issues in the infant. There are conflicting studies concerning …

Healthy pregnancies are fundamental to healthy populations, but very few therapies to
improve pregnancy outcomes are available. Fundamental concepts—for example …

Background There are few medicines in clinical use for managing preterm labor or
preventing spontaneous preterm birth from occurring. We previously developed two target …

In November, 2022, WHO published updated recommendations for antenatal corticosteroids
and tocolytic therapy1, 2 in response to new evidence about these interventions that …

Complications posed by preterm birth (delivery before 37 weeks of pregnancy) are a leading
cause of newborn morbidity and mortality. The previous discovery and validation of an …

Introduction To evaluate the effect of antenatal magnesium sulfate (MgSO4) on mortality and
morbidity outcomes related to the gastrointestinal system (GI) in preterm infants. Methods …

Objective To develop target product profiles (TPPs) for new medicines for preterm birth
prevention and preterm labour management that address the real‐world need of women …

During labor, monocytes infiltrate massively the myometrium and differentiate into
macrophages secreting high levels of reactive oxygen species and of pro-inflammatory …

Importance Women with arrested preterm labor (APTL) are at very high risk for spontaneous
preterm delivery (SPTD), the leading cause of neonatal mortality and morbidity. To date, no …

Background: Antenatal magnesium sulphate (MgSO4) therapy given to women at risk of
preterm birth reduced the risk of cerebral palsy in early childhood. However, its effect on …